Clinical use of rituximab in haematological malignancies. - Wikidata - awgldk - TriplyDB

Clinical use of rituximab in haematological malignancies.

Clinical use of rituximab in haematological malignancies.

http://www.wikidata.org/entity/Q35561014

about

Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts Intraocular lymphoma: update on diagnosis and management.Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.Cancer vaccines: a clinical perspective.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.Rituximab (Rituxan).Rituximab and minimal change nephrotic syndrome: a therapeutic option.Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy.An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.

P2860

Q28280510-3349B573-1481-4C3A-9765-51ABEC47BC29 Q28728722-E2F867E3-B3CA-4106-A870-F20AC894D25B Q35892007-807EF878-D53E-46BE-8E55-8D12109711BC Q36079223-DD195616-9A3C-4562-A929-9C95B3A439AF Q36554683-FAE5D9B4-59B2-458F-9D26-51EB9F5F8C6B Q36724093-92C77AF5-3A61-4413-93A6-6ACB11C31FC4 Q36879135-EBCEE4C4-C3B5-49C1-91C2-9BCE7D4280C2 Q37744225-EC6CA214-D4F7-4200-8BBD-162F9E0A5BAF Q37879578-E07ADB22-984D-483E-AA47-CFD6FC7F4FCA Q40600575-14BEE199-4153-4ECB-B42F-123FFF803645 Q41760763-0FD876D1-9B5C-4562-B00A-5D9E2FC5BAC0

P2860

Clinical use of rituximab in haematological malignancies.

http://www.wikidata.org/entity/Q35561014

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Clinical use of rituximab in haematological malignancies.

@ast

Clinical use of rituximab in haematological malignancies.

@en

type

label

Clinical use of rituximab in haematological malignancies.

@ast

Clinical use of rituximab in haematological malignancies.

@en

prefLabel

Clinical use of rituximab in haematological malignancies.

@ast

Clinical use of rituximab in haematological malignancies.

@en

P1433

Q35561014-87F7A0B9-383E-466C-8679-270FDB9113D3

P1476

Q35561014-55ED6C3F-3AE6-4530-A89F-0F1754CE2991

P2093

Q35561014-0F882B3A-09C1-4EE8-ACDF-C22FD5D3BEB1

Q35561014-9E3ECD77-C022-4FC6-89BF-8FFF16ADE4A2

Q35561014-B5D47226-4B53-4994-A2C0-1584B8E8AB28

P2860

Q35561014-08161CE5-0203-4401-B83A-FCC747C01C79

Q35561014-11EEECC0-4802-4836-ACAA-C9A873C40314

Q35561014-14670C16-6C1D-4434-AC5D-42B1541C04D7

Q35561014-34822E4F-4191-47D4-88ED-2957F96894F9

Q35561014-4163A57A-7A1E-46D0-B6F1-00D93CACDDC2

Q35561014-546B23C2-1BDE-4EA8-8558-B1AF89DBDED1

Q35561014-54986142-F03A-4C92-8D2C-53EF8E50EEC0

Q35561014-67EE5217-EF4B-44AD-9CE9-F4B7D4A6F342

Q35561014-697FCEF4-9CD5-4492-BB4E-B2F3EACA411C

Q35561014-70462A26-0E49-4645-9D10-67DAA8C3879D

P2888

Q35561014-36CE14A5-1B9D-490A-B57D-F2B7DBFBBD90

P304

Q35561014-70D18AE6-AC6E-4C3F-80C0-21D98575BFB2

P31

Q35561014-3D36B2C7-6F23-4922-8F2E-C539CAABD50D

Q35561014-F4036080-53BE-48AA-9E91-5EEDDF2A6F4A

P356

Q35561014-3A8A8FF7-E8C4-401A-84BD-7FC5FC26CD35

P407

Q35561014-DA92B81E-AD7D-42FD-989C-F44B2CE989DD

P433

Q35561014-D58F37AF-8DFE-4090-9744-AEEFD420699C

P478

Q35561014-42F85458-A56D-434D-AA8D-5FB53AE3AA1A

P577

Q35561014-0A22C223-2D0B-41D3-86E3-3A7AB70D3B1B

Q35561014-133A3E09-EFFF-4C34-BF0C-8D7A02A83418

P5875

Q35561014-ECB407A8-F9AD-4A77-BC73-21B1F60EC6F4

P698

Q35561014-D6F6DB90-AD15-4FB3-8574-B8DA00E60A73

P921

Q35561014-41797F81-EAAF-4616-AE58-CA4C664351D7

Q35561014-7D6A90DE-6D94-4FAA-900F-90EDE0664ADB

Q35561014-937765C3-2D1B-445B-9203-8CCBA79C291D

Q35561014-ED195B67-B590-4F3D-9EA2-5F9FA0E1D32F

P932

Q35561014-6261DDAA-7A44-427E-B5A5-BA3FD91E7E36

P356

P1433

British Journal of Cancer

P1476

Clinical use of rituximab in haematological malignancies.

@en

P2093

A Goldstone

http://www.w3.org/2001/XMLSchema#string

I Avivi

http://www.w3.org/2001/XMLSchema#string

S Robinson

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Rituximab: enhancing stem cell transplantation in mantle cell lymphoma.

Rituximab: mechanism of action and resistance.

First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.

Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma.

Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.

Rituximab dose-escalation trial in chronic lymphocytic leukemia.

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

P2888

P304

1389-1394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6601187

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2003-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9048520

http://www.w3.org/2001/XMLSchema#string

P698

14562003

http://www.w3.org/2001/XMLSchema#string

P921

hematologic cancer

monoclonal antibody

P932

2394352

http://www.w3.org/2001/XMLSchema#string